


Anatibant 2HCl

Chemical Properties

CAS No. :	209788-45-4
Formula:	C ₃₄ H ₃₆ Cl ₂ N ₆ O ₅ ·2ClH
Molecular Weight:	784.58
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Anatibant 2HCl is a small molecule bradykinin B2 receptor antagonist for the treatment of neurological disorders and may be used in the study of brain injury.
Targets(IC50)	Bradykinin Receptor
In vivo	Anatibant (3.0 mg/kg b.w.; Subcutaneous Injection; Male C57/Bl6 mice (CCI)) was administrated as a subcutaneous bolus 15 min and 8h after TBI. ICP was measured 3, 6, and 10 h after injury, and contusion volume was quantified 24 h after trauma. Our data demonstrate a significant reduction of ICP (16.6+/-1.67 mmHg vs. 24.40+/-3.58 mmHg; n=6; p=0.002) and of contusion volume 24 h after trauma (28.28+/-5.18 mm ³ vs. 35.0+/-3.32 mm ³ n=7; p=0.003) in treated mice. Therefore we conclude, that inhibition of bradykinin B2 receptors seems to be a promising treatment option, and might therefore be investigated in clinical trials for the treatment of TBI.[1]

Solubility Information

Solubility	DMSO: 55 mg/mL (70.1 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.2746 mL	6.3728 mL	12.7457 mL
5 mM	0.2549 mL	1.2746 mL	2.5491 mL
10 mM	0.1275 mL	0.6373 mL	1.2746 mL
50 mM	0.0255 mL	0.1275 mL	0.2549 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zweckberger K, et al. Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. *Neurosci Lett.* 2009;454(2): 115-117.

Kläsner B, et al. Therapeutic window of bradykinin B2 receptor inhibition after focal cerebral ischemia in rats. *Neurochem Int.* 2006;49(5):442-447.

Ongali B, et al. Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier. *J Neurotrauma.* 2006;23(5):696-707.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481